Nothing Special   »   [go: up one dir, main page]

DE602005017285D1 - - Google Patents

Info

Publication number
DE602005017285D1
DE602005017285D1 DE602005017285T DE602005017285T DE602005017285D1 DE 602005017285 D1 DE602005017285 D1 DE 602005017285D1 DE 602005017285 T DE602005017285 T DE 602005017285T DE 602005017285 T DE602005017285 T DE 602005017285T DE 602005017285 D1 DE602005017285 D1 DE 602005017285D1
Authority
DE
Germany
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005017285T
Inventor
Denis Drapeau
Yen-Tung Luan
James R Mercer
Wenge Wang
Daniel R Lasko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ireland Pharmaceuticals
Original Assignee
Wyeth Research Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35500648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005017285(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Research Ireland Ltd filed Critical Wyeth Research Ireland Ltd
Publication of DE602005017285D1 publication Critical patent/DE602005017285D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/32Amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/90Serum-free medium, which may still contain naturally-sourced components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/90Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95Protein-free medium and culture conditions

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE602005017285T 2004-08-27 2005-08-26 Active DE602005017285D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60537904P 2004-08-27 2004-08-27
PCT/US2005/030439 WO2006026447A2 (en) 2004-08-27 2005-08-26 PRODUCTION OF TNFR-Ig FUSION PROTEIN

Publications (1)

Publication Number Publication Date
DE602005017285D1 true DE602005017285D1 (de) 2009-12-03

Family

ID=35500648

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602005017285T Active DE602005017285D1 (de) 2004-08-27 2005-08-26
DE602005020076T Active DE602005020076D1 (de) 2004-08-27 2005-08-26 Herstellung von TNFR-Fc

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602005020076T Active DE602005020076D1 (de) 2004-08-27 2005-08-26 Herstellung von TNFR-Fc

Country Status (38)

Country Link
US (1) US7300773B2 (de)
EP (2) EP1992697B1 (de)
JP (3) JP2008511330A (de)
KR (1) KR100988451B1 (de)
CN (2) CN102876761A (de)
AR (2) AR050537A1 (de)
AT (2) ATE461285T1 (de)
AU (1) AU2005280036B2 (de)
BR (1) BRPI0514694B8 (de)
CA (1) CA2578138C (de)
CL (1) CL2017000577A1 (de)
CR (2) CR8998A (de)
CY (2) CY1109721T1 (de)
DE (2) DE602005017285D1 (de)
DK (2) DK1781802T3 (de)
EC (1) ECSP077354A (de)
EG (1) EG26922A (de)
ES (2) ES2335518T3 (de)
GT (2) GT200500233A (de)
HK (2) HK1099941A1 (de)
HN (1) HN2005000485A (de)
HR (2) HRP20100011T1 (de)
IL (1) IL181588A (de)
MX (1) MX2007002381A (de)
MY (1) MY137803A (de)
NO (1) NO344785B1 (de)
NZ (1) NZ579208A (de)
PE (2) PE20060815A1 (de)
PL (2) PL1781802T3 (de)
PT (2) PT1992697E (de)
RS (2) RS51072B (de)
RU (1) RU2458988C2 (de)
SI (2) SI1992697T1 (de)
SV (1) SV2006002211A (de)
TW (1) TWI364458B (de)
UA (1) UA89383C2 (de)
WO (1) WO2006026447A2 (de)
ZA (1) ZA200701672B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
PE20070796A1 (es) * 2005-10-24 2007-08-15 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
US20070231895A1 (en) * 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
TR201807021T4 (tr) * 2006-07-13 2018-06-21 Wyeth Llc Geliştirilmiş glikosilasyon şablonuna sahip pıhtılaşma faktörü ıx?un üretilmesi.
MX2009004519A (es) * 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
AU2007323978B2 (en) * 2006-11-08 2012-08-16 Wyeth Llc Rationally designed media for cell culture
DK2115126T3 (en) 2007-03-02 2015-05-04 Wyeth Llc Use of copper and glutamate in cell culture for the preparation of polypeptides
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
ES2624185T3 (es) 2007-04-26 2017-07-13 Chugai Seiyaku Kabushiki Kaisha Método de cultivo celular que utiliza un medio enriquecido con aminoácidos
JP5739324B2 (ja) * 2008-04-17 2015-06-24 ワイス・エルエルシー 骨形成タンパク質の産生増進法
WO2009127098A1 (zh) * 2008-04-18 2009-10-22 上海中信国健药业有限公司 一种浓缩培养液及其使用方法
US8318416B2 (en) * 2008-08-08 2012-11-27 Biogen Idec Ma Inc. Nutrient monitoring and feedback control for increased bioproduct production
JP5930542B2 (ja) 2009-08-11 2016-06-08 ジェネンテック, インコーポレイテッド グルタミンフリー細胞培養培地におけるタンパク質の生産
CA2782320A1 (en) * 2009-12-02 2011-06-09 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life of fc fusion proteins
MX2012012528A (es) 2010-04-26 2012-11-23 Novartis Ag Proceso de cultivo celular mejorado.
MX2012012525A (es) 2010-04-26 2012-11-23 Novartis Ag Medio de cultivo mejorado.
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
JP2014503495A (ja) * 2010-11-15 2014-02-13 バイオジェン アイデック インコーポレイテッド 過負荷結合および溶出クロマトグラフィによる選択生成物アイソフォームの富化および濃縮
WO2012147053A1 (en) 2011-04-29 2012-11-01 Biocon Research Limited A method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
WO2012170938A1 (en) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life
MX2014004732A (es) 2011-10-18 2015-05-15 Coherus Biosciences Inc Formulaciones de etanercept estabilizadas con meglumina.
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
MX351991B (es) 2011-10-21 2017-11-03 Pfizer Adicion de hierro para mejorar cultivo celular.
SG11201405013RA (en) * 2012-02-22 2014-09-26 Nvip Pty Ltd Tumour necrosis factor receptor fusion proteins and methods of using the same
AU2013290289B2 (en) 2012-07-09 2018-03-29 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
WO2014043103A1 (en) 2012-09-11 2014-03-20 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
CA2907771C (en) 2013-03-26 2023-01-10 Coherus Biosciences, Inc. Perfusion method for manufacturing etanercept
KR101439195B1 (ko) 2013-04-18 2014-09-12 동아대학교 산학협력단 에셰리키아 콜리 a-53 균주를 이용하여 섬유소 분해효소의 생산성을 향상시키는 공정
CA2926049C (en) * 2013-10-11 2023-09-05 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
EP3683316A1 (de) * 2014-01-30 2020-07-22 Coherus Biosciences, Inc. Perfusionsmedien
US20160347787A1 (en) 2014-02-04 2016-12-01 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
CA2969225C (en) 2014-12-01 2023-08-22 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
CN105777897A (zh) * 2015-03-20 2016-07-20 广东东阳光药业有限公司 一种cho细胞收获液的前处理方法
EP3277797B1 (de) * 2015-04-01 2020-08-19 Boehringer Ingelheim International GmbH Zellkulturmedium
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
BR112019007858A2 (pt) 2016-10-21 2019-07-02 Amgen Inc formulações farmacêuticas e métodos para produzir as mesmas
CN110484487A (zh) * 2019-08-21 2019-11-22 安徽欣乐生物技术有限公司 一种适用于cho细胞培养用无蛋白培养基及其培养方法
EP4267717A1 (de) 2020-12-22 2023-11-01 Amgen Inc. Zellkulturverfahren
CN115073607A (zh) * 2021-03-12 2022-09-20 上海康岱生物医药技术股份有限公司 Tnfr2与baff受体的融合蛋白
CN114480492B (zh) * 2022-01-28 2023-04-21 景泽生物医药(合肥)股份有限公司 一种重组人抗体融合蛋白的制备方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
AU632065B2 (en) * 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
CA2067194C (en) 1989-10-05 2003-03-18 Glenn Kawasaki Cell-free synthesis and isolation of novel genes and polypeptides
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5538983A (en) 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5156964A (en) 1990-08-16 1992-10-20 Cetus Corporation Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB2251249B (en) 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
GB9118664D0 (en) 1991-08-30 1991-10-16 Celltech Ltd Cell culture
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JP3504963B2 (ja) 1993-10-22 2004-03-08 智靖 羅 抗ヒト高親和性IgE受容体モノクローナル抗体に係るアミノ酸配列をコードするDNA断片
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) * 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US20020012991A1 (en) * 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
WO2000023082A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
AU2002257162A1 (en) 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
DE60230736D1 (de) 2001-04-30 2009-02-26 Lilly Co Eli HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9;
JP2004532642A (ja) 2001-06-13 2004-10-28 ジェネンテック・インコーポレーテッド 動物細胞の培養方法と動物細胞でのポリペプチド産生
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
CA2476654A1 (en) 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
MXPA04008150A (es) 2002-02-21 2005-06-17 Wyeth Corp Gasp1: una proteina que contiene dominio de folistatina.
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1507556B1 (de) 2002-05-02 2016-07-27 Wyeth Holdings LLC Calicheamicin-derivat-trägerkonjugate
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta

Also Published As

Publication number Publication date
IL181588A (en) 2010-12-30
DK1781802T3 (da) 2010-01-25
SI1992697T1 (sl) 2010-07-30
DE602005020076D1 (de) 2010-04-29
EP1992697B1 (de) 2010-03-17
CA2578138C (en) 2010-10-05
BRPI0514694B8 (pt) 2021-05-25
PT1992697E (pt) 2010-04-21
WO2006026447A3 (en) 2006-04-20
KR20070069140A (ko) 2007-07-02
BRPI0514694A (pt) 2008-06-17
NO20071570L (no) 2007-05-23
EP1781802B1 (de) 2009-10-21
CN101061231B (zh) 2012-09-26
WO2006026447A9 (en) 2006-06-01
JP2008511330A (ja) 2008-04-17
ATE461285T1 (de) 2010-04-15
SV2006002211A (es) 2006-10-04
RS51072B (sr) 2010-10-31
PT1781802E (pt) 2010-01-04
CN101061231A (zh) 2007-10-24
MY137803A (en) 2009-03-31
PL1781802T3 (pl) 2010-03-31
RS51255B (sr) 2010-12-31
WO2006026447A2 (en) 2006-03-09
US20060121569A1 (en) 2006-06-08
CR8998A (es) 2007-11-23
CY1110092T1 (el) 2015-01-14
NO344785B1 (no) 2020-04-27
AU2005280036B2 (en) 2011-11-03
UA89383C2 (ru) 2010-01-25
EP1781802A2 (de) 2007-05-09
TWI364458B (en) 2012-05-21
CY1109721T1 (el) 2014-08-13
KR100988451B1 (ko) 2010-10-18
PE20060815A1 (es) 2006-09-14
BRPI0514694B1 (pt) 2019-04-24
HN2005000485A (es) 2009-06-09
CA2578138A1 (en) 2006-03-09
ATE446376T1 (de) 2009-11-15
US7300773B2 (en) 2007-11-27
RU2458988C2 (ru) 2012-08-20
HRP20100271T1 (hr) 2010-06-30
HK1121497A1 (en) 2009-04-24
EG26922A (en) 2014-12-25
AU2005280036A1 (en) 2006-03-09
AR088824A2 (es) 2014-07-10
HK1099941A1 (en) 2007-08-31
RU2007108717A (ru) 2008-10-10
CR20120560A (es) 2012-12-04
GT200500234A (es) 2006-10-10
AR050537A1 (es) 2006-11-01
IL181588A0 (en) 2007-07-04
JP2012095672A (ja) 2012-05-24
ES2335518T3 (es) 2010-03-29
PL1992697T3 (pl) 2010-08-31
MX2007002381A (es) 2007-06-15
PE20100448A1 (es) 2010-06-22
EP1992697A1 (de) 2008-11-19
TW200619388A (en) 2006-06-16
CN102876761A (zh) 2013-01-16
NZ579208A (en) 2012-01-12
DK1992697T3 (da) 2010-05-17
SI1781802T1 (sl) 2010-01-29
ECSP077354A (es) 2007-05-30
CL2017000577A1 (es) 2017-12-01
GT200500233A (es) 2006-03-09
JP5921910B2 (ja) 2016-05-24
JP2016056214A (ja) 2016-04-21
ZA200701672B (en) 2012-04-24
ES2341390T3 (es) 2010-06-18
HRP20100011T1 (hr) 2010-02-28

Similar Documents

Publication Publication Date Title
BE2024C508I2 (de)
BE2024C511I2 (de)
BE2022C549I2 (de)
BE2020C513I2 (de)
BE2020C517I2 (de)
BE2019C540I2 (de)
BE2019C548I2 (de)
BE2018C045I2 (de)
BE2017C027I2 (de)
BE2017C023I2 (de)
BE2017C002I2 (de)
BE2016C067I2 (de)
BE2016C014I2 (de)
BE2015C041I2 (de)
BE2015C038I2 (de)
BE2015C014I2 (de)
BE2014C071I2 (de)
BE2014C064I2 (de)
BE2014C063I2 (de)
BE2015C066I2 (de)
BE2014C010I2 (de)
BE2013C071I2 (de)
BE2013C021I2 (de)
BE2019C535I2 (de)
BR122015024347A2 (de)

Legal Events

Date Code Title Description
8363 Opposition against the patent
R082 Change of representative

Ref document number: 1781802

Country of ref document: EP

Representative=s name: REITSTOETTER, KINZEBACH & PARTNER (GBR), DE

R081 Change of applicant/patentee

Ref document number: 1781802

Country of ref document: EP

Owner name: PFIZER IRELAND PHARMACEUTICALS, IE

Free format text: FORMER OWNER: WYETH RESEARCH IRELAND LTD., NEWBRIDGE, IE

Effective date: 20120824

R082 Change of representative

Ref document number: 1781802

Country of ref document: EP

Representative=s name: REITSTOETTER, KINZEBACH & PARTNER (GBR), DE

Effective date: 20120824